A case-by-case protocol of membranous nephropathy treatment with endovenous infusion of high doses of human immunoglobulins

Nephron - Clinical Practice

Volumn 108, Issue 2, 2008, Pages

  Floccari, F ^a   Cosentini, V ^a   Giacobbe, M ^a   Coppolino, G ^a   Campo, S ^a   Bolignano, D ^a   Tripodo, D ^a   Nostro, L ^a   Buemi, M ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Intra venous immunoglobulins; Membranous nephropathy; Progression of chronic renal failure; Proteinuria

Indexed keywords

CHOLESTEROL; FIBRINOGEN; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; PLASMA PROTEIN; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY DISEASE; MALE; PRIORITY JOURNAL; REMISSION; RISK FACTOR; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; MEMBRANOUS GLOMERULONEPHRITIS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PROTEINURIA; RETROSPECTIVE STUDY;

ADULT; AGED; BLOOD PROTEINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROTEINURIA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SERUM ALBUMIN; STATISTICS, NONPARAMETRIC;

EID: 39549107174     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113528     Document Type: Article

References (20)

1. Ponticelli C, Passerini P: Membranous nephropathy; in Ponticelli C, Glassock RJ (eds): Treatment of Primary Glomerulonephritis. New York, Oxford University Press, 1997, pp 147-185.
2. Schieppati A, et al: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993;329:85-89.
3. Ponticelli C, et al: Treatment of the nephrotic syndrome associated with primary glomerulonephritis. Kidney Int 1994;46:595-604.
4. Wassertein AG: Membranous glomerulonephritis. J Am Soc Nephrol 1997;6:664-674.
5. Wehrmann M, et al: Long-term prognosis of chronic idiopathic membranous glomerulonephritis: an analysis of 334 cases with particular regard to tubulo-interstitial changes. Clin Nephrol 1989;31:67-76.
6. Imai H: Medical decision-making in membranous nephropathy: how to use limited clinical research evidence in patient management. Clin Exp Nephrol 2005;9:206-211.
7. Kazatchkine MD, et al: Immunomodulation of autoimmune and inflammatory diseases with intra-venous immune globulin. N Engl J Med 2001;345:747-755.
8. Monova D, et al: Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: clinical experience lasting 15 years. Nephron 2002;90:262-266.
9. Akalin E, et al: Intravenous immunoglobulin treatment in a kidney transplant patient with chronic allograft nephropathy. Transplantation 2005;79:257-258.
10. Rostoker G, et al: High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Ann Intern Med 1994;120:476-484.
11. Meissner M, et al: Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int 2000;19:199-201.
12. Levy Y, et al: A study of 20 SLE patients with ivIg: clinical and serologic response. Lupus 1999;8:705-712.
13. Tuso P, et al: Treatment of ANCA-positive systemic vasculitis and glomerulonephritis with pooled IvIg. Am J Kidney Dis 1992;20:504-508.
14. Muso E, et al: IVIg therapy in MPO-ANCA related polyangiitis with rapidly progressive GN in Japan. Jpn J Infect Dis 2004;57:S17-S18.
15. Palla R, et al: Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety. Clin Nephrol 1991;35:98-104.
16. Yokoyama H, et al: The short- and long-term outcomes of membranous nephropathy treated with intravenous immuneglobuline therapy. Nephrol Dial Transplant 1999;14:2379-2386.
17. Nangaku M, et al: Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. Kidney Int 1996;50:2054-2062.
18. Ono M, Bolland S, Tempst P, Ravetch JV: Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγIIB. Nature 1996;383, 263-266.
19. Lemieux R, Bazin R, N'eron S: Molecular Immunology 2005;42:839-848.
20. Dalakas MC: Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002;59:S13-S21.